In March 2019, the US Food and Drug Administration (FDA) approved a nasal spray formulation of esketamine for the treatment of resistant depression in adults. Esketamine is the S-enantiomer of ketamine, an FDA-approved anaesthetic, known to cause dissociation and, occasionally, hallucinations. While ketamine has not been approved for depression in the USA or in any other country, it has been used off-label in cases of severe depression. This commentary critically reviewed the evidence on esketamine submitted to the FDA, aiming to draw implications for clinical practice, research and regulatory science.

Esketamine for treatment resistant depression: a trick of smoke and mirrors?

Gastaldon, C
;
Papola, D;Ostuzzi, G;Barbui, C
2020

Abstract

In March 2019, the US Food and Drug Administration (FDA) approved a nasal spray formulation of esketamine for the treatment of resistant depression in adults. Esketamine is the S-enantiomer of ketamine, an FDA-approved anaesthetic, known to cause dissociation and, occasionally, hallucinations. While ketamine has not been approved for depression in the USA or in any other country, it has been used off-label in cases of severe depression. This commentary critically reviewed the evidence on esketamine submitted to the FDA, aiming to draw implications for clinical practice, research and regulatory science.
Esketamine; FDA; evidence-based medicine; regulatory policies; treatment-resistant depression
File in questo prodotto:
File Dimensione Formato  
esketamine_for_treatment_resistant_depression_a_trick_of_smoke_and_mirrors.pdf

accesso aperto

Descrizione: CC BY 4.0 publisher's version
Tipologia: Versione dell'editore
Licenza: Creative commons
Dimensione 293.67 kB
Formato Adobe PDF
293.67 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1008522
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 21
social impact